department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

MADRIGAL PHARMACEUTICALS, INC. ($MDGL) · pharmadog

PUBLIC COMPANY

$MDGLMADRIGAL PHARMACEUTICALS, INC.

West Conshohocken, PA, USupdated 2h ago

SEC EDGAR ↗Yahoo Finance ↗

community read0 votes

pipeline

2

marketed

1

phase 3

0

catalysts ytd

1

approvals ytd

0

recalls ytd

0

Pipeline(2)

pipeline depth2 products

1Marketed1Unknown

Metabolic Dysfunction-Associated Steatohepatitis (MASH or…

1 INDICATIONS AND USAGE REZDIFFRA is indicated in conjunc…

Thyroid hormone receptor beta

Upcoming

no upcoming catalysts on record

Recent(90d)

earnings (1)

MADRIGAL PHARMACEUTICALS, INC. earnings

MADRIGAL PHARMACEUTICALS, INC.

view all catalysts →

🐶 Hiring Signal

No open roles indexed yet — view MADRIGAL PHARMACEUTICALS, INC. jobs →

News

no news has mentioned this company yet

identifiers

ticker

$MDGL

SEC CIK

0001157601

country

US

source

sec_tickers

mentioned in

0news items

entity-linker matched

Data sources

SEC EDGAR · openFDA

last refreshed 1m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

$MDGL530.98+0.55%

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Active trials

phase3A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)active not recruitingn=845
phase2Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASHrecruitingn=120
—Rezdiffra Pregnancy and Lactation Registryrecruitingn=10
phase2Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH)completedn=125
phase2Study of MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)completedn=116
phase1A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses (6 Days) of 100 mg Resmetirom in Subjects With Severe Renal Impairment and in Matched Healthy Control Subjects With Normal Renal Functioncompletedn=28
phase3A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)active not recruitingn=1,000
phase3A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosisactive not recruitingn=1,759

more trials →

$MDGL530.98+0.55%

Insider activity

source: SEC Form 4

open-market buys + sells

Mar 6, 26SELLSibold William John· President and CEO1,663 sh @ $431.94−$718K↗
Mar 6, 26SELLDier Mardi· EVP and CFO646 sh @ $431.94−$279K↗
Mar 6, 26SELLTaub Rebecca· director491 sh @ $431.94−$212K↗
Mar 6, 26SELLHuntsman Carole· Chief Commercial Officer419 sh @ $431.94−$181K↗
Mar 6, 26SELLDier Mardi· EVP and CFO420 sh @ $426.86−$179K↗
Mar 6, 26SELLKelley Shannon T· General Counsel360 sh @ $431.94−$155K↗
Mar 6, 26SELLDier Mardi· EVP and CFO160 sh @ $434.20−$69K↗
Mar 6, 26SELLDier Mardi· EVP and CFO160 sh @ $429.00−$69K↗
Mar 6, 26SELLDier Mardi· EVP and CFO120 sh @ $430.90−$52K↗
Mar 6, 26SELLDier Mardi· EVP and CFO116 sh @ $432.56−$50K↗
Mar 6, 26SELLDier Mardi· EVP and CFO80 sh @ $436.69−$35K↗
Mar 6, 26SELLDier Mardi· EVP and CFO80 sh @ $435.31−$35K↗
Mar 6, 26SELLDier Mardi· EVP and CFO80 sh @ $427.85−$34K↗
Mar 6, 26SELLDier Mardi· EVP and CFO40 sh @ $437.65−$18K↗
Mar 6, 26SELLDier Mardi· EVP and CFO40 sh @ $429.58−$17K↗
Mar 6, 26SELLDier Mardi· EVP and CFO40 sh @ $425.08−$17K↗
Mar 2, 26SELLDier Mardi· EVP and CFO1,183 sh @ $427.21−$505K↗

routine RSU / option mechanics (3)

Mar 4, 26grantDier Mardi · EVP and CFO5,215 sh
Mar 4, 26grantDier Mardi · EVP and CFO6,519 sh
Mar 4, 26grantSibold William John · President and CEO14,995 sh